Truist Financial Corp Purchases 1,423 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Truist Financial Corp lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 37,195 shares of the company’s stock after buying an additional 1,423 shares during the quarter. Truist Financial Corp’s holdings in Neurocrine Biosciences were worth $4,901,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Assenagon Asset Management S.A. boosted its position in Neurocrine Biosciences by 120.6% during the third quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company’s stock worth $65,761,000 after purchasing an additional 319,564 shares during the period. Westfield Capital Management Co. LP boosted its position in Neurocrine Biosciences by 73.0% during the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after purchasing an additional 273,952 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Neurocrine Biosciences by 59.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock worth $77,892,000 after purchasing an additional 256,920 shares during the period. Jennison Associates LLC boosted its position in Neurocrine Biosciences by 86.0% during the third quarter. Jennison Associates LLC now owns 409,475 shares of the company’s stock worth $46,066,000 after purchasing an additional 189,345 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in Neurocrine Biosciences by 81.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 410,103 shares of the company’s stock worth $54,035,000 after purchasing an additional 184,660 shares during the period. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on NBIX. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, May 1st. HC Wainwright upped their price target on Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday. Barclays upped their price target on Neurocrine Biosciences from $150.00 to $169.00 and gave the stock an “overweight” rating in a report on Thursday. BMO Capital Markets upped their price target on Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a report on Thursday. Finally, Mizuho upped their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, February 8th. Six research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $147.88.

Neurocrine Biosciences Trading Up 0.6 %

Shares of NBIX opened at $140.71 on Monday. Neurocrine Biosciences, Inc. has a 1 year low of $89.04 and a 1 year high of $148.37. The stock has a market cap of $14.16 billion, a P/E ratio of 38.76 and a beta of 0.28. The stock’s 50-day moving average price is $137.37 and its two-hundred day moving average price is $129.00.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm had revenue of $515.20 million for the quarter, compared to analysts’ expectations of $518.52 million. During the same quarter last year, the business earned $0.88 earnings per share. The company’s revenue was up 25.0% compared to the same quarter last year. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.78 EPS for the current year.

Insider Activity

In other news, insider David W. Boyer sold 1,328 shares of Neurocrine Biosciences stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $135.41, for a total transaction of $179,824.48. Following the transaction, the insider now owns 4,895 shares in the company, valued at approximately $662,831.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider David W. Boyer sold 1,328 shares of Neurocrine Biosciences stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $135.41, for a total transaction of $179,824.48. Following the transaction, the insider now owns 4,895 shares in the company, valued at approximately $662,831.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ingrid Delaet sold 200 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $140.00, for a total value of $28,000.00. Following the completion of the sale, the insider now owns 7,507 shares in the company, valued at approximately $1,050,980. The disclosure for this sale can be found here. Insiders have sold 181,547 shares of company stock worth $25,039,887 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.